SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 17, 2010
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On
February 16, 2010, Oramed Pharmaceuticals Inc. issued a press release announcing
that John M. Amatruda, M.D. has joined Oramed’s Scientific Advisory Board,
enhancing Oramed’s talented and experienced scientific team.
Dr.
Amatruda was the Senior Vice President and Franchise Head, Diabetes and Obesity
at Merck Research Laboratories. He is board certified in internal
medicine, endocrinology and metabolism and has a proven track record in
academics and pharmaceutical discovery research and development, including
several novel candidate compounds, INDs, translational studies, development
programs and four NDAs.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
(d) Exhibits
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated February 16,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
||
|
Dated:
February 16, 2010
|
||
|
By:
|
/s/
Nadav Kidron
|
|
|
Nadav
Kidron
|
||
|
President,
CEO and
Director
|
||
Exhibit
Index
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
Release dated February 16,
2010.
|
Oramed
Pharmaceuticals Expands Scientific Advisory Board
With
the Appointment of John Amatruda, M.D.
Dr.
Amatruda is the former Senior Vice President and Franchise Head of the Diabetes
and Obesity Unit at Merck & Co.
JERUSALEM,
Israel – February 16, 2010 – Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com), a
developer of oral delivery systems, announced today that John M. Amatruda, M.D.
has joined Oramed’s Scientific Advisory Board, enhancing Oramed’s talented and
experienced scientific team.
Dr.
Amatruda was the Senior Vice President and Franchise Head, Diabetes and Obesity
at Merck Research Laboratories. He is board certified in internal medicine,
endocrinology and metabolism and has a proven track record in academics and
pharmaceutical discovery research and development, including several novel
candidate compounds, INDs, translational studies, development programs and four
NDAs.
In
joining the Scientific Advisory Board, Dr. Amatruda will provide Oramed access
to his extensive successful pharmaceutical industry experience in the
development and approval of novel drugs. Additionally, his experience
in licensing, structuring agreements and managing collaborations will prove
invaluable to the Company.
"Dr.
Amatruda is a very highly respected pharmaceutical executive and we are honored
that he is joining our Scientific Advisory Board,” said Nadav Kidron, Chief
Executive Officer of Oramed. “His expertise and knowledge in the diabetes field
will assist us in moving forward with the development of our product
pipeline.”
Dr.
Amatruda commented that “it is a pleasure to join the Scientific Advisory Board
of Oramed. Oramed’s development of proprietary technology for the oral delivery
of peptide pharmaceuticals will be an important advance in the treatment of many
chronic diseases that require injectables, including diabetes.”
Dr.
Amatruda is joined on the Scientific Advisory Board by the following existing
members: Derek LeRoith, Ph.D.; Nir Brazilai, M.D.; Ele Ferrannini,
M.D., Ph.D.; and Avram Hershko, M.D., Ph.D.
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed’s technology is based on over 25 years of
research by top research scientists at Jerusalem’s Hadassah Medical Center. The
Company’s corporate and R&D headquarters are based in
Jerusalem.
For more
information, please visit www.oramed.com
Forward-looking
statements
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company’s ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
statements.
Company
and Investor Relation Contacts:
Oramed
Pharmaceuticals
Tara
Horn
Cell: +
972-54-334-318
Office: +
972-2-566-0001
Email:
tara@oramed.com